Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Finished Goods (2022 - 2025)

Jin Medical International's Finished Goods history spans 4 years, with the latest figure at $915839.0 for Q3 2025.

  • For Q3 2025, Finished Goods fell 33.02% year-over-year to $915839.0; the TTM value through Sep 2025 reached $915839.0, down 33.02%, while the annual FY2025 figure was $915839.0, 33.02% down from the prior year.
  • Finished Goods for Q3 2025 was $915839.0 at Jin Medical International, down from $1.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $2.1 million in Q3 2022 and bottomed at $820949.0 in Q3 2023.
  • The 4-year median for Finished Goods is $1.1 million (2024), against an average of $1.3 million.
  • The largest annual shift saw Finished Goods plummeted 59.97% in 2023 before it skyrocketed 66.57% in 2024.
  • A 4-year view of Finished Goods shows it stood at $2.1 million in 2022, then plummeted by 59.97% to $820949.0 in 2023, then surged by 66.57% to $1.4 million in 2024, then plummeted by 33.02% to $915839.0 in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Finished Goods are $915839.0 (Q3 2025), $1.4 million (Q3 2024), and $820949.0 (Q3 2023).